The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What are targeted therapies and when can they be used in the treatment of acute myeloid leukemia?
Jordi Esteve
July 22, 2022
During the EHA 2022 Congress, Know AML spoke with Jordi Esteve, Hospital Clínic de Barcelona, Barcelona, ES. We asked, What are targeted therapies and when can they be used in the treatment of acute myeloid leukemia?
Esteve begins by explaining what targeted molecules are, and what these agents can achieve, including their clinical benefits compared to other therapies. Esteve discusses venetoclax, new therapeutic combinations, and molecular targets being explored in clinical trials to address unmet needs in the acute myeloid leukemia field.
To what extent do you agree with the following statements?
Please rate between 1 and 5, with 1 being 'strongly disagree' and 5 being 'strongly agree'.
